An impaired immune tolerance animal model distinguishes the potential of troglitazone/pioglitazone and tolcapone/entacapone to cause IDILI

Toxicological Sciences

Volumn 161, Issue 2, 2018, Pages 412-420

  Mak, Alastair ^a   Kato, Ryuji ^b   Weston, Kyle ^a   Hayes, Anthony ^c   Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

Adverse drug reactions; Danger associated molecular pattern molecules; Idiosyncratic drug induced liver injury; Immunotoxicology; Inflammasome; Liver; Systems toxicology

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTACAPONE; INFLAMMASOME; PIOGLITAZONE; TOLCAPONE; TROGLITAZONE; CATECHOL DERIVATIVE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; NITRILE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IN VIVO STUDY; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; SUPERNATANT; TOXIC HEPATITIS; ANIMAL; C57BL MOUSE; CELL LINE; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTIBODIES, MONOCLONAL; CATECHOLS; CELL LINE; CHEMICAL AND DRUG INDUCED LIVER INJURY; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; FEMALE; HEPATOCYTES; HUMANS; IMMUNE TOLERANCE; INFLAMMASOMES; MACROPHAGES; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRILES; PIOGLITAZONE; PROGRAMMED CELL DEATH 1 RECEPTOR; SEVERITY OF ILLNESS INDEX; TOLCAPONE; TROGLITAZONE;

EID: 85041501694     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfx219     Document Type: Article

References (24)

1. Akasaki, Y., Liu, G., Matundan, H. H., Ng, H., Yuan, X., Zeng, Z., Black, K. L., and Yu, J. S. (2006). A peroxisome proliferatoractivated receptor-gamma agonist, troglitazone, facilitates caspase-8 and-9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J. Biol. Chem. 281, 6165-6174
2. Bettigole, S. E., and Glimcher, L. H. (2015). Endoplasmic reticulum stress in immunity. Annu. Rev. Immunol. 33, 107-138
3. Borges, N. (2003). Tolcapone-related liver dysfunction: Implications for use in Parkinson's disease therapy. Drug Saf. 26, 743-747
4. Chakraborty, M., Fullerton, A. M., Semple, K., Chea, L. S., Proctor, W. R., Bourdi, M., Kleiner, D. E., Zeng, X., Ryan, P. M., Dagur, P. K., et al. (2015). Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment. Hepatology 62, 546-557
5. Forsberg, M., Lehtonen, M., Heikkinen, M., Sovalainen, J., Järvinen, T., and Männistö, P. T. (2003). Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: A comparative study in the rat. J. Pharmacol. Exp. Ther. 304, 498-506
6. Guo, H., Callaway, J. B., and Ting, J. P. (2015). Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677-687
7. Haasio, K., Nissinen, E., Sopanen, L., and Heinonen, E. H. (2002). Different toxicological profile of two COMT inhibitors in vivo: The role of uncoupling effects. J. Neural. Transm. 109, 1391-1401
8. Hasumura, S., Sujino, H., Nagamori, S., and Kameda, H. (1988). Establishment and characterization of a human hepatocellular carcinoma cell line JHH-4. Hum. Cell 1, 98-100
9. Heymann, F., and Tacke, F. (2016). Immunology in the liver-from homeostasis to disease. Nat. Rev. Gastroenterol. Hepatol. 13, 88-110
10. Kato, R., and Uetrecht, J. (2017). Supernatant from hepatocyte cultures with drugs that cause idiosyncratic liver injury activates macrophage inflammasomes. Chem. Res. Toxicol. 30, 1327-1332
11. Lobach, A. R., and Uetrecht, J. (2014). Clozapine promotes the proliferation of granulocyte progenitors in the bone marrow leading to increased granulopoiesis and neutrophilia in rats. Chem. Res. Toxicol. 27, 1109-1119
12. Luyendyk, J. P., Maddox, J. F., Cosma, G. N., Ganey, P. E., Cockerell, G. L., and Roth, R. A. (2003). Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 307, 9-16
13. Mak, A., and Uetrecht, J. (2015a). The combination of anti-CTLA-4 and PD1-/-mice unmasks the potential of isoniazid and nevirapine to cause liver injury. Chem. Res. Toxicol. 28, 2287-2291
14. Mak, A., and Uetrecht, J. (2015b). The role of CD8 T Cells in amodiaquine-induced liver injury in PD1-/-mice cotreated with anti-CTLA-4. Chem. Res. Toxicol. 28, 1567-1573
15. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045
16. Metushi, I. G., Hayes, M. A., and Uetrecht, J. (2015). Treatment of PD-1-/-mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 61, 1332-1342
17. Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Lightfoot-Dunn, R., and Hamadeh, H. K. (2010). Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118, 485-500
18. Ng, W., Lobach, A. R. M., Zhu, X., Chen, X., Liu, F., Metushi, I. G., Sharma, A., Li, J., Cai, P., Ip, J., et al. (2012). Animal Models of Idiosyncratic Drug Reactions. Adv. Pharmacol. 63, 81-135
19. Oda, S., Matsuo, K., Nakajima, A., and Yokoi, T. (2016). A novel cell-based assay for the evaluation of immune-and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. Toxicol. Lett. 241, 60-70
20. Regev, A. (2014). Drug-induced liver injury and drug development: Industry perspective. Semin. Liver Dis. 34, 227-239
21. Senior, J. R. (2014). Evolution of the food and drug administration approach to liver safety assessment for new drugs: Current status and challenges. Drug Saf 37, 9-17
22. Szabo, G., and Petrasek, J. (2015). Inflammasome activation and function in liver disease. Nat. Rev. Gastroenterol. Hepatol. 12, 387-400
23. Uetrecht, J. (2007). Idiosyncratic drug reactions: Current understanding. Annu. Rev. Pharmacol. Toxicol. 47, 513-539
24. Weston, J. K., and Uetrecht, J. (2014). Activation of inflammasomes by agents causing idiosyncratic skin reactions: A possible biomarker. Chem. Res. Toxicol. 27, 949-951